课题基金 / 基金详情

IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER

IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
RIFNG 和 RIL 2 在卵巢癌 IP 过继免疫治疗中的 IP 启动
批准号:
6121100
负责人:
RALPH Stuart FREEDMAN
金额:
$1.51万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

RALPH Stuart FREEDMAN的其他基金

相似基金

相关文献

中文摘要
翻译
我们在UCRC拨款下进行的翻译研究的要点和 涉及腹膜内免疫治疗的包括以下内容: (A)22名患者接受了干扰素-1和rIL-2的ip注射 多数患者无明显不良反应。每2个人中有一个 有微小残留病变的患者(定义为单个肿瘤&1 cm 腹膜无多发性转移瘤,目前为一例 年份没有疾病的临床或放射学证据。另外两名患者 肿瘤稳定6个月。 (2)HLAI、II类抗原表达显著 经干扰素-1处理后,卵巢肿瘤细胞的增殖活性增加。 然而,在某些患者中,人类白细胞抗原I类或II类减少 在注射IL-2后。这些变化似乎是相互关联的 随着腹膜IL-10和可能的转化生长因子-β浓度的增加 体液。 (C)在我的实验室工作的一名研究生已确认并 腹腔液中分泌IL-10的单核细胞的特征 患者(提交给AACR和美国医学会的摘要 免疫学家)。这是一个重要的发现,因为它提供了一个可能的 在体内控制IL-10产生的未来努力的目标。 (D)我们还表明,92%的RNA提取物中存在IL-2信息 而干扰素-信息仅出现在22%的病例中。我们的 研究结果表明,T细胞在体内可能只被部分激活。 (E)因此,我们已寻找其他因素,以解释 体内T细胞激活不完全。我们已经确定了一群 然而,作为树突状细胞的表型特征的细胞, 这些细胞缺乏CD80或CD80低表达,并有其他 暗示不成熟的特征。 (F)根据我们的研究结果,干扰素可上调MHC抗原- 虽然B7.1共刺激抗原表达不足,但我们 正在探索一种基因修饰的自体肿瘤疫苗在 一项新的临床试验。疫苗是从自体肿瘤细胞中提取的 感染了编码该基因的金丝雀痘载体 CD80。新鲜的肿瘤细胞已经用干扰素预处理,然后感染 与ALVAC-hB7.1载体(巴斯德·梅里厄)连接。我们观察到了一个 MHC、CD80、ICAM升高。自体的这些特征 疫苗应该有利于T细胞在体内更完全的激活。这个 临床试验设计已获得RAC、NCI和FDA的批准 应计已经开始了。预计一些患者将会 在UCRC接受治疗。 (G)在城市资源中心现正进行的另一项试验中,我们 新的免疫导向细胞因子IP-rIL-12的作用研究 支持TH1效应的反应(这有可能推动 将前细胞毒性CTL分化为细胞毒性CTL)。我们目前在 第二剂量水平以及药理学和免疫学研究 是与这场审判有关的。 (H)如果这两个审判都达到了不同的目标,将考虑 IL-12联合ALVAC-hB7.1未来临床应用 审判。 (I)我们还在实验室开展了几项研究,以确定 我们可以控制免疫抑制分子的产生,转化生长因子- 和IL-10。这些药物包括反义寡核苷酸与 脂质体制剂,其次是使用来自 我们已经证明的芳香脂肪酸基团可以减少产量 转化生长因子-β的表达。 (J)最后,M.D.Anderson正在制定一项临床方案 癌症中心解决IP治疗问题的一般问题。这一计划将 处理更基本的问题,如毒品渗透、毒品 在组织中的浓度,其目标是获得改善的结果 IP疗法建立在更好地理解药效学原理的基础上。
英文摘要
Highlights of our translational studies conducted under the UCRC grant and involving intraperitoneal immunotherapy include the following: (A) Twenty-two patients received IP injections of IFN- followed by rIL-2 without significant adverse effects in most patients. One out of 2 patients with minimal residual disease (defined as individual tumors <1cm and absence of multiple metastases in the peritoneum, currently after one year has no clinical or radiologic evidence of disease. Two other patients had stability of their tumors for 6 months. (B) Expression of HLA class I and class II antigens were significantly increased on ovarian tumor cells following the IP treatment with IFN- . However, in certain patients, either HLA class I or class II decreased following the injections of IP IL-2. These changes appear to be correlated with increased concentrations of IL-10 and possibly TGF- B in peritoneal fluids. (C) A graduate student who works in my laboratory has identified and characterized an IL-10 secreting monocyte in the peritoneal fluid of patients (abstract submitted to AACR and American Association of Immunologists). This is an important finding since it provides a possible target for future efforts to control IL-10 production in vivo. (D) We have also shown that IL-2 message is present in 92% of RNA extracts of the PEC, whereas IFN- message was present in only 22% of cases. Our findings suggest that T cells may only be partially activated in vivo. (E) We have therefore looked for other factors that may account for incomplete T cell activation in vivo. We have identified a population of cells that are phenotypically characteristic of dendritic cells, however, these cells lack CD80 or have low expression of CD80 and have other features suggesting immaturity. (F) Based on our findings that MHC antigens can be upregulated by IFN- although expression of the B7.1 costimulatory antigens are deficient, we are exploring the effects of a gene modified autologous tumor vaccine in a new clinical trial. The vaccine is derived from autologous tumor cells that have been infected with a canarypox vector that encodes the gene for CD80. Fresh tumor cells have been pretreated with IFN- and then infected with the ALVAC-hB7.1 vector (Pasteur Merieux). We have observed an increase in MHC, CD80 and ICAM. These characteristics in an autologous vaccine should favor more complete activation of T cells in vivo. The clinical trial design has been approved by the RAC, the NCI and the FDA and accrual has started. It is anticipated that some of the patients will be treated in the UCRC. (G) In a separate trial which is being conducted at the UCRC, we are studying the effects of IP rIL-12, a novel cytokine that can direct immune responses in favor of TH1 effects (this has a potential to drive differentiation of precytotoxic CTL to cytotoxic CTL). We are presently at the second dose level and pharmacologic as well as immunologic studies are being conducted in association with this trial. (H) If both of these trials attain separate objectives, consideration will be given to the combination of IL-12 with ALVAC-hB7.1 in a future clinical trial. (I) We have also initiated several studiess in our laboratory to determine of we can control the production of the immunosuppressive molecules, TGF- and IL-10. These include antisense oligonucleotides combined with liposomal formulation, and secondly the use of small molecules from the aromatic fatty acid group that which we have shown can reduce production of TGF-B . (J) Finally, a clinical program is being developed at M. D. Anderson Cancer Center to address IP therapy issues in general. This program will deal with more fundamental issues such as drug penetration, drug concentration in tissues and its goal is to obtain improved outcomes with IP therapies based on better understanding of pharmacodynamic principles.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autologous therapeutic tumor vaccine + IFN-gamma
Phase ii intraperitoneal rhIL 12
Phase ii intraperitoneal rhIL 12
B7.1 COSTIMULATION IN OVARIAN CANCER
海外基金